Intech Investment Management LLC Acquires 291,675 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Intech Investment Management LLC boosted its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 1,429.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 312,080 shares of the company’s stock after purchasing an additional 291,675 shares during the quarter. Intech Investment Management LLC owned 0.07% of GE HealthCare Technologies worth $24,398,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Darwin Wealth Management LLC acquired a new position in GE HealthCare Technologies during the third quarter valued at approximately $31,000. Continuum Advisory LLC boosted its holdings in shares of GE HealthCare Technologies by 101.8% in the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after buying an additional 168 shares during the period. Bank of Jackson Hole Trust acquired a new position in shares of GE HealthCare Technologies in the fourth quarter valued at approximately $32,000. Flagship Wealth Advisors LLC acquired a new position in shares of GE HealthCare Technologies in the fourth quarter valued at approximately $34,000. Finally, OFI Invest Asset Management acquired a new position in shares of GE HealthCare Technologies in the fourth quarter valued at approximately $34,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Wells Fargo & Company upped their price target on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their target price for the stock from $95.00 to $103.00 in a report on Wednesday, January 8th. The Goldman Sachs Group upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and increased their target price for the stock from $85.00 to $100.00 in a report on Tuesday, March 11th. Finally, Citigroup increased their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $98.75.

GE HealthCare Technologies Stock Up 0.6 %

NASDAQ GEHC opened at $82.47 on Tuesday. The business has a fifty day moving average price of $87.27 and a two-hundred day moving average price of $86.12. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. GE HealthCare Technologies Inc. has a fifty-two week low of $74.51 and a fifty-two week high of $94.80. The stock has a market capitalization of $37.71 billion, a PE ratio of 19.05, a PEG ratio of 3.19 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.19. The firm had revenue of $5.32 billion during the quarter, compared to analysts’ expectations of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. Equities analysts expect that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current fiscal year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.